Ensign Peak Advisors
BTAI icon

Ensign Peak Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Ensign Peak Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-338
Closed -$64K – 1846
2022
Q3 		$64K Hold
338
– – ﹤0.01% 2166
2022
Q2 		$71K Hold
338
– – ﹤0.01% 2024
2022
Q1 		$113K Hold
338
– – ﹤0.01% 2005
2021
Q4 		$110K Buy
+338
New +$145K ﹤0.01% 2045

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Ensign Peak Advisors's BTAI Position: Q4 2022 in Review

Ensign Peak Advisors sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 338 shares — an estimated $64K sold.

Ensign Peak Advisors first reported a position in BTAI in Q4 2021 and held it in 4 quarters. The position peaked at $113K in Q1 2022. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

  • Ensign Peak Advisors reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 338 BioXcel Therapeutics shares in Q4 2022, an estimated $64K.
  • Ensign Peak Advisors first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's BioXcel Therapeutics position peaked at $113K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.